Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Qiagen ( (QGEN) ) has shared an update.
Qiagen N.V. has announced a release of voting rights as informed by the Netherlands Authority for the Financial Markets (AFM). The notification involves Barclays Plc and details various types of shares and voting rights held indirectly by Barclays entities. This announcement reflects on the distribution of shares and potential voting rights, which may influence Qiagen’s shareholder dynamics and market perception.
The most recent analyst rating on (QGEN) stock is a Buy with a $51.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
Qiagen N.V. operates in the biotechnology industry, specializing in the development and sale of products for sample and assay technologies. The company focuses on providing solutions for molecular diagnostics, applied testing, academic and pharmaceutical research, and is listed on multiple stock exchanges including Frankfurt, NYSE, and SIX.
Average Trading Volume: 1,482,791
Technical Sentiment Signal: Strong Buy
Current Market Cap: $10.19B
See more data about QGEN stock on TipRanks’ Stock Analysis page.